Aptuit and Regulus Therapeutics have entered a strategic provider relationship for a broad range of discovery and development services to support Regulus programs targeting microRNAs.

Dr. Goldman chief executive officer, Aptuit, said, “Aptuit provides high quality standalone and integrated solutions in the target to candidate, and candidate to IND phases of development. Our scientific expertise and high standards in chemistry and biology improve the probability of success. In addition, our scale and fully integrated end to end approach reduces timeline and costs, and are an excellent fit with Regulus focus on microRNA. We believe our support will allow Regulus to rapidly progress more programs in parallel.”

Dr. Timothy Wright, Regulus chief R&D officer, said, “Aptuit is recognized as a leading integrated service provider in the discovery and development space. We are delighted to engage Aptuit across multiple service areas to accelerate the progress of our most promising microRNA programs, achieving anticipated milestones and driving efficiency.”